Evidence map›Paper›PMID 38078733›Full record

ArticleJournal of virology2024

Transcriptional regulation of the HIV-1 inhibitory factor human mannose receptor 1 by the myeloid-specific transcription factor PU.1.

Rosa Mallorson, Eri Miyagi, Sandra Kao, Sayaka Sukegawa, Hideki Saito, Helena Fabryova, Luciana Morellatto Ruggieri, Sonia Mediouni, Susana T Valente, Klaus Strebel

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Rosa Mallorson *Viral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.ORCID 0000-0002-1644-0321
Eri Miyagi *Viral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.ORCID 0000-0001-9561-2269
Sandra KaoViral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
Sayaka SukegawaDepartment of Molecular Virology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Hideki SaitoViral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
Helena FabryovaViral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
Luciana Morellatto RuggieriViral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
Sonia MediouniDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida, USA.
Susana T ValenteDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida, USA.ORCID 0000-0002-7854-7554
Klaus StrebelViral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.ORCID 0000-0002-2827-8923
National Institutes of Health · USThe Herbert Wertheim UF Scripps Institute for Biomedical Innovation & TechnologyTokyo Medical and Dental University · JP

Funding

Molecular Analysis Of Retroviral Genes And Their ProductsZIAAI000669 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI STREBEL, KLAUS · 2009 to 2025
$25.2M
Mode of action of a new Tat HIV-1 inhibitorR01AI097012 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2012 to 2022
$7.5M
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3M
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuseand Aging on Cognitive ImpairmentR01DA052027 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI NDHLOVU, LISHOMWA C, NIXON, DOUGLAS F · 2020 to 2024
$3.7M
Molecular Analysis Of Retroviral Genes &Their ProductsZ01AI000669 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI STREBEL, KLAUS · 1993 to 2008
$852k
Validation and characterization of Tat inhibitors identified through HTSR21AI158296 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2021 to 2022
$509k
Intramural NIH HHS Z01 AI000669NIAID NIH HHS R01 AI097012NIAID NIH HHS R01 AI167732NIAID NIH HHS R21 AI158296NIDA NIH HHS R01 DA052027
6 · The paper itself

Abstract

HIV-1 infection of human macrophages leads to the downmodulation of human mannose receptor 1 (hMRC1), a cell-surface glycoprotein that is involved in the host innate immune response. We previously reported that downmodulation of hMRC1 involves the transactivator of transcription (Tat)-dependent transcriptional silencing of the hMRC1 promoter. However, the inhibitory effect of Tat on hMRC1 transcription was indirect and involved inhibition of the transcriptional activator PU.1, which normally upregulates hMRC1 expression in macrophages and other myeloid cells. We cloned a 284-bp fragment of the hMRC1 promoter, and within it, we identified four PU.1 box elements. We assessed the relative contribution of each of the four PU.1 boxes to PU.1-dependent transcriptional regulation and, surprisingly, found that only one of the four PU.1 boxes [PU.1(b)] was critically required for PU.1-mediated upregulation of luciferase expression. Transfer of this PU.1 box to a heterologous promoter conferred PU.1 responsiveness to an otherwise PU.1 insensitive promoter. Electrophoretic mobility shift assays identified this PU.1 box as a direct binding site for PU.1 both in the context of the hMRC1 promoter and the heterologous promoter. Furthermore, mutational analysis of the PU.1 protein identified the C-terminal DNA-binding domain in PU.1 as the region responsible for interaction with the PU.1 box. Recombinant HIV-1 Tat protein did not bind to the hMRC1 promoter element but efficiently interfered with the binding of PU.1 protein to the hMRC1 promoter. Thus, Tat is likely to inhibit the formation of active PU.1 transcription complexes, presumably by binding to and depleting common transcriptional cofactors.IMPORTANCEHIV-1 infection of cells results in the modulation of cellular gene expression by virus-encoded proteins in a manner that benefits the virus. We reported that HIV-1 transactivator of transcription (Tat) dysregulates the expression of the human mannose receptor 1 (hMRC1). hMRC1 is involved in the innate immune response of macrophages to foreign pathogens. Tat does not act directly on the hMRC1 promoter but instead inhibits PU.1, a cellular transcription factor regulating hMRC1 gene expression. Here, we characterize the PU.1-dependent regulation of hMRC1 expression. We identified four potential PU.1 binding sites in the hMRC1 promoter region but found that only one, PU.1(b), functioned as a true binding site for PU.1. Transfer of the PU.1(b) box to a heterologous promoter did not activate this promoter

Indexed as

HIV-1Mannose ReceptorProto-Oncogene ProteinsTrans-ActivatorsHumansProto-Oncogene Protein Spi-1Transcriptional ActivationTranscription FactorsTranscription, GeneticMannose ReceptorProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-ActivatorsTranscription FactorsHIV-1mannose receptor promoterPU.1Tattranscriptional regulatortranscription factor

Identifiers

PMID38078733
PMCPMC10804955
OpenAlexW4389559353

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.